Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17142082 | 0.98 | DPP4 (0.37) | DPP4DPP8DPP9MEN1ALDH1A1 | |
| SCHEMBL18427191 | 0.78 | RIPK1 (0.40) | DPP4DPP8DPP9GLRA1CNR2 | |
| SCHEMBL22248829 | 0.77 | CHRNA4 (0.56) | — | |
| SCHEMBL14152461 | 0.74 | RIPK1 (0.38) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL14151612 | 0.73 | RIPK1 (0.35) | DPP4MEN1ALDH1A1CYP1A2THRB | |
| SCHEMBL19204374 | 0.72 | DPP4 (0.34) | DPP4DPP8DPP9GLRA1 | |
| SCHEMBL28439050 | 0.70 | CNR2 (0.30) | CNR2 | |
| SCHEMBL9979887 | 0.69 | — | — | |
| SCHEMBL9946443 | 0.65 | CHRNB2 (0.60) | DPP4DPP8DPP9MEN1ALDH1A1 | |
| SCHEMBL12424653 | 0.65 | GAA (0.47) | DPP4ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3126349-B1 | 5,6-DISUBSTITUTED PYRIDINE-2-CARBOXAMIDES AS CANNABINOID RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2019-06-26 | — | — | EP | disclosed |
| US-20160376237-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-12-29 | — | — | US | disclosed |
| WO-2015150438-A1 | 5,6-DISUBSTITUTED PYRIDINE-2-CARBOXAMIDES AS CANNABINOID RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376237-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS4, NDUFV1 | DPP4 2226/4885DPP8 3515/4885DPP9 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.